Origami Therapeutics, Inc.
Developing drugs to degrade toxic proteins for neurodegenerative diseases.
Developing drugs to degrade toxic proteins for neurodegenerative diseases.
Origami Therapeutics, Inc., founded with a mission to halt neurodegeneration, focuses on developing novel protein degraders to eliminate toxic proteins from the body. Leveraging proprietary human disease models, the company aims to select small molecules with high clinical success potential. Their primary target is Huntington’s disease, a severe genetic disorder. Origami Therapeutics is dedicated to creating next-generation, disease-modifying therapies that target and degrade disease-related proteins.
Notable figures affiliated with Origami Therapeutics include experienced scientists and biotech entrepreneurs who have contributed significantly to the field of neurodegenerative diseases. The company has attracted investments from leading biotech venture capital firms, underscoring its innovative approach. Key achievements include the identification of small molecules with promising therapeutic potential for Huntington’s disease. Origami Therapeutics is poised to make a significant impact on the treatment of neurodegenerative disorders by pioneering new therapeutic strategies.
Companies similar to Origami Therapeutics, Inc. include 76Bio, Biotheryx, Chaperone Therapeutics and Neomorph.
Origami Therapeutics, Inc. was founded in 2015.
Origami Therapeutics, Inc.'s headquarters is located in San Diego, CA, US.
Origami Therapeutics, Inc.'s most recent funding round was for $500k (USD) in March 2022.
As of Mar 22, 2022, Origami Therapeutics, Inc. has raised a total of $500k (USD).
Origami Therapeutics, Inc. has 4 employees as of Aug 23, 2023.
Chaperone Therapeutics
